Online inquiry

IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2594MR)

This product GTTS-WQ2594MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MPL gene. The antibody can be applied in Chronic immune (idiopathic) thrombocytopenic purpurea (ITP) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005373.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4352
UniProt ID P40238
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ2594MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14504MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RYI-018
GTTS-WQ15837MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ2706MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG103
GTTS-WQ14561MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aCD1919
GTTS-WQ13917MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN2477
GTTS-WQ9878MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ7304MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FPA-008
GTTS-WQ6176MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CP-751871
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW